Sudhakar, Niranjan

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 1,304

Identification of the Clinical Development Candidate MRTX849 , a Covalent KRASG12C Inhibitor for the Treatment of Cancer

Fell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., Burkard, M. R., et al. (2020) · Journal of Medicinal Chemistry

Protein Kinase Regulation and GTPase SignalingHeterocyclic Compound Synthesis and Bioactivity

Cited by 653

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

Briere, D. M., Li, S., Calinisan, A., Sudhakar, N., Aranda, R., Hargis, L., Peng, D. H., Deng, J., Engstrom, L. D., Hallin, J., et al. (2021) · Molecular Cancer Therapeutics

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 168

Discovery of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity

Fell, J. B., Fischer, J. P., Baer, B. R., Ballard, J., Blake, J. F., Bouhana, K., Brandhuber, B. J., Briere, D. M., Burgess, L. E., Burkard, M. R., et al. (2018) · ACS Medicinal Chemistry Letters

Protein Kinase Regulation and GTPase SignalingHeterocyclic Compound Synthesis and Bioactivity

Cited by 120

TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors

Edwards, A. C., Stalnecker, C. A., Jean Morales, A., Taylor, K. E., Klomp, J. E., Klomp, J. A., Waters, A. M., Sudhakar, N., Hallin, J., Tang, T. T., et al. (2023) · Cancer Research

Hippo pathway signaling and YAP/TAZProtein Kinase Regulation and GTPase Signaling

Cited by 91

Abstract LB-C09: the KRASG12C inhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination with anti-PD-1 therapy in a syngeneic mouse model

Briere, D. M., Calinisan, A., Aranda, R., Sudhakar, N., Hargis, L., Gatto, S., Fernandez-Banet, J., Pavlicek, A., Engstrom, L. D., Hallin, J., et al. (2019) · Molecular Cancer Therapeutics

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 13

Abstract B30: Structure-based drug discovery of MRTX1257, a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer

Marx, M. A., Baer, B. R., Ballard, J., Blake, J. F., Bouhana, K., Briere, D. M., Burgess, L. E., Burkhard, M. R., Chiang, H., Chicarelli, M. J., et al. (2020) · Molecular Cancer Research

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 11